Prostate-Specific Ets (PSE) factor

A novel marker for detection of metastatic breast cancer in axillary lymph nodes

M. Mitas, K. Mikhitarian, Loretta H Jophlin, M. A. Lockett, L. Kelley, A. Hill, W. E. Gillanders, D. J. Cole

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Prostate Specific Ets factor is a recently identified transcriptional activator that is overexpressed in prostate cancer. To determine whether this gene is overexpressed in breast cancer, we performed a virtual Northern blot using data available online at the Cancer Genome Anatomy Project website. Ninety-five SAGE libraries were probed with a unique sequence tag to the Prostate Specific Ets gene. The results indicate that Prostate Specific Ets is expressed in 14 out of 15 breast cancer libraries (93%), nine out of 10 prostate cancer libraries (90%), three out of 40 libraries from other cancers (7.5%), and four out of 30 normal tissue libraries (13%). To determine the possibility that the Prostate Specific Ets gene is a novel marker for detection of metastatic breast cancer in axillary lymph nodes, quantitative real-time RT-PCR analyses were performed. The mean level of Prostate Specific Ets expression in lymph nodes containing metastatic breast cancer (n=22) was 410-fold higher than in normal lymph node (n=51). A receiver operator characteristic curve analysis indicated that Prostate Specific Ets was overexpressed in 18 out of 22 lymph nodes containing metastatic breast cancer (82%). The receiver operator characteristic curve analysis also indicated that the diagnostic accuracy of the Prostate Specific Ets gene for detection of metastatic breast cancer in axillary lymph nodes was 0.949. These results provide evidence that Prostate Specific Ets is a potentially informative novel marker for detection of metastatic breast cancer in axillary lymph nodes, and should be included in any study that involves molecular profiling of breast cancer.

Original languageEnglish (US)
Pages (from-to)899-904
Number of pages6
JournalBritish journal of cancer
Volume86
Issue number6
DOIs
StatePublished - Mar 18 2002

Fingerprint

Prostate
Lymph Nodes
Breast Neoplasms
Libraries
Genes
Prostatic Neoplasms
Northern Blotting
Real-Time Polymerase Chain Reaction
Neoplasms
Anatomy
Genome

Keywords

  • Gene overexpression
  • Real-time RT-PCR
  • Receiver operator characteristic curve
  • SYBR Green I
  • Virtual Northern blot

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mitas, M., Mikhitarian, K., Jophlin, L. H., Lockett, M. A., Kelley, L., Hill, A., ... Cole, D. J. (2002). Prostate-Specific Ets (PSE) factor: A novel marker for detection of metastatic breast cancer in axillary lymph nodes. British journal of cancer, 86(6), 899-904. https://doi.org/10.1038/sj.bjc.6600190

Prostate-Specific Ets (PSE) factor : A novel marker for detection of metastatic breast cancer in axillary lymph nodes. / Mitas, M.; Mikhitarian, K.; Jophlin, Loretta H; Lockett, M. A.; Kelley, L.; Hill, A.; Gillanders, W. E.; Cole, D. J.

In: British journal of cancer, Vol. 86, No. 6, 18.03.2002, p. 899-904.

Research output: Contribution to journalArticle

Mitas, M, Mikhitarian, K, Jophlin, LH, Lockett, MA, Kelley, L, Hill, A, Gillanders, WE & Cole, DJ 2002, 'Prostate-Specific Ets (PSE) factor: A novel marker for detection of metastatic breast cancer in axillary lymph nodes', British journal of cancer, vol. 86, no. 6, pp. 899-904. https://doi.org/10.1038/sj.bjc.6600190
Mitas, M. ; Mikhitarian, K. ; Jophlin, Loretta H ; Lockett, M. A. ; Kelley, L. ; Hill, A. ; Gillanders, W. E. ; Cole, D. J. / Prostate-Specific Ets (PSE) factor : A novel marker for detection of metastatic breast cancer in axillary lymph nodes. In: British journal of cancer. 2002 ; Vol. 86, No. 6. pp. 899-904.
@article{4cfd1c3352204a0ca5b21c5065b9a50a,
title = "Prostate-Specific Ets (PSE) factor: A novel marker for detection of metastatic breast cancer in axillary lymph nodes",
abstract = "Prostate Specific Ets factor is a recently identified transcriptional activator that is overexpressed in prostate cancer. To determine whether this gene is overexpressed in breast cancer, we performed a virtual Northern blot using data available online at the Cancer Genome Anatomy Project website. Ninety-five SAGE libraries were probed with a unique sequence tag to the Prostate Specific Ets gene. The results indicate that Prostate Specific Ets is expressed in 14 out of 15 breast cancer libraries (93{\%}), nine out of 10 prostate cancer libraries (90{\%}), three out of 40 libraries from other cancers (7.5{\%}), and four out of 30 normal tissue libraries (13{\%}). To determine the possibility that the Prostate Specific Ets gene is a novel marker for detection of metastatic breast cancer in axillary lymph nodes, quantitative real-time RT-PCR analyses were performed. The mean level of Prostate Specific Ets expression in lymph nodes containing metastatic breast cancer (n=22) was 410-fold higher than in normal lymph node (n=51). A receiver operator characteristic curve analysis indicated that Prostate Specific Ets was overexpressed in 18 out of 22 lymph nodes containing metastatic breast cancer (82{\%}). The receiver operator characteristic curve analysis also indicated that the diagnostic accuracy of the Prostate Specific Ets gene for detection of metastatic breast cancer in axillary lymph nodes was 0.949. These results provide evidence that Prostate Specific Ets is a potentially informative novel marker for detection of metastatic breast cancer in axillary lymph nodes, and should be included in any study that involves molecular profiling of breast cancer.",
keywords = "Gene overexpression, Real-time RT-PCR, Receiver operator characteristic curve, SYBR Green I, Virtual Northern blot",
author = "M. Mitas and K. Mikhitarian and Jophlin, {Loretta H} and Lockett, {M. A.} and L. Kelley and A. Hill and Gillanders, {W. E.} and Cole, {D. J.}",
year = "2002",
month = "3",
day = "18",
doi = "10.1038/sj.bjc.6600190",
language = "English (US)",
volume = "86",
pages = "899--904",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Prostate-Specific Ets (PSE) factor

T2 - A novel marker for detection of metastatic breast cancer in axillary lymph nodes

AU - Mitas, M.

AU - Mikhitarian, K.

AU - Jophlin, Loretta H

AU - Lockett, M. A.

AU - Kelley, L.

AU - Hill, A.

AU - Gillanders, W. E.

AU - Cole, D. J.

PY - 2002/3/18

Y1 - 2002/3/18

N2 - Prostate Specific Ets factor is a recently identified transcriptional activator that is overexpressed in prostate cancer. To determine whether this gene is overexpressed in breast cancer, we performed a virtual Northern blot using data available online at the Cancer Genome Anatomy Project website. Ninety-five SAGE libraries were probed with a unique sequence tag to the Prostate Specific Ets gene. The results indicate that Prostate Specific Ets is expressed in 14 out of 15 breast cancer libraries (93%), nine out of 10 prostate cancer libraries (90%), three out of 40 libraries from other cancers (7.5%), and four out of 30 normal tissue libraries (13%). To determine the possibility that the Prostate Specific Ets gene is a novel marker for detection of metastatic breast cancer in axillary lymph nodes, quantitative real-time RT-PCR analyses were performed. The mean level of Prostate Specific Ets expression in lymph nodes containing metastatic breast cancer (n=22) was 410-fold higher than in normal lymph node (n=51). A receiver operator characteristic curve analysis indicated that Prostate Specific Ets was overexpressed in 18 out of 22 lymph nodes containing metastatic breast cancer (82%). The receiver operator characteristic curve analysis also indicated that the diagnostic accuracy of the Prostate Specific Ets gene for detection of metastatic breast cancer in axillary lymph nodes was 0.949. These results provide evidence that Prostate Specific Ets is a potentially informative novel marker for detection of metastatic breast cancer in axillary lymph nodes, and should be included in any study that involves molecular profiling of breast cancer.

AB - Prostate Specific Ets factor is a recently identified transcriptional activator that is overexpressed in prostate cancer. To determine whether this gene is overexpressed in breast cancer, we performed a virtual Northern blot using data available online at the Cancer Genome Anatomy Project website. Ninety-five SAGE libraries were probed with a unique sequence tag to the Prostate Specific Ets gene. The results indicate that Prostate Specific Ets is expressed in 14 out of 15 breast cancer libraries (93%), nine out of 10 prostate cancer libraries (90%), three out of 40 libraries from other cancers (7.5%), and four out of 30 normal tissue libraries (13%). To determine the possibility that the Prostate Specific Ets gene is a novel marker for detection of metastatic breast cancer in axillary lymph nodes, quantitative real-time RT-PCR analyses were performed. The mean level of Prostate Specific Ets expression in lymph nodes containing metastatic breast cancer (n=22) was 410-fold higher than in normal lymph node (n=51). A receiver operator characteristic curve analysis indicated that Prostate Specific Ets was overexpressed in 18 out of 22 lymph nodes containing metastatic breast cancer (82%). The receiver operator characteristic curve analysis also indicated that the diagnostic accuracy of the Prostate Specific Ets gene for detection of metastatic breast cancer in axillary lymph nodes was 0.949. These results provide evidence that Prostate Specific Ets is a potentially informative novel marker for detection of metastatic breast cancer in axillary lymph nodes, and should be included in any study that involves molecular profiling of breast cancer.

KW - Gene overexpression

KW - Real-time RT-PCR

KW - Receiver operator characteristic curve

KW - SYBR Green I

KW - Virtual Northern blot

UR - http://www.scopus.com/inward/record.url?scp=0037128696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037128696&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600190

DO - 10.1038/sj.bjc.6600190

M3 - Article

VL - 86

SP - 899

EP - 904

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -